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The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the treatment of colorectal
cancer. In this study, we investigate the molecular mechanisms of action of oxaliplatin to identify means of predicting response to this
agent. Exposure of colon cancer cells to oxaliplatin resulted in G2/M arrest and apoptosis. Immunofluorescent staining demonstrated
that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c
release into the cytosol. Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by
inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association. Targeted inactivation of Bax or p53 in
HCT116 cells resulted in significantly increased resistance to oxaliplatin. However, the mutational status of p53 was unable to predict
response to oxaliplatin in a panel of 30 different colorectal cancer cell lines. In contrast, the expression profile of these 30 cell lines,
assessed using a 9216-sequence cDNA microarray, successfully predicted the apoptotic response to oxaliplatin. A leave-one-out
cross-validation approach was used to demonstrate a significant correlation between experimentally observed and expression profile
predicted apoptosis in response to clinically achievable doses of oxaliplatin (R¼0.53; P¼0.002). In addition, these microarray
experiments identified several genes involved in control of apoptosis and DNA damage repair that were significantly correlated with
response to oxaliplatin.
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Oxaliplatin is a third generation diaminocyclohexane (DACH)
platinum compound that forms mainly intrastrand links between
two adjacent guanine residues or a guanine and an adenine,
disrupting DNA replication and transcription (Fink et al, 1997).
Although the related platinum compounds, cisplatin and carbo-
platin, are generally ineffective in the treatment of colorectal
cancer, oxaliplatin has been shown to be effective in the treatment
of this disease and it is commonly used to treat patients
unresponsive to 5-fluorouracil (5FU) based therapy. However,
the details underlying the cytotoxic effects of oxaliplatin remain
poorly understood.
Exposure of tumour cells to several chemotherapeutic agents,
including oxaliplatin, has been shown to induce programmed cell
death or apoptosis (Searle et al, 1975; Lowe and Lin, 2000;
Gourdier et al, 2002; Johnstone et al, 2002). In mammalian cells,
the signalling cascades leading to apoptosis can be divided into
two broad groups. The intrinsic pathway is characterised by the
central role of the mitochondria in the initiation of the caspase
cascade executing the apoptotic program (Desagher and Martinou,
2000). Pro- and antiapoptotic Bcl-2 family members play a pivotal
role in the intrinsic apoptotic cascade (Narita et al, 1998; Gross
et al, 1999). Upon exposure to some apoptotic stimuli, proapop-
totic Bcl-2 family members such as Bax, which normally reside in
the cytosol, are relocated to the outer mitochondrial membrane
where they lead to the release of apoptotic factors from the
mitochondria and ultimately to caspase activation and an
apoptotic cell death (Li et al, 1997; Zou et al, 1997). The tumour
suppressor gene p53 has been shown to directly regulate the
expression levels of Bax (Miyashita and Reed, 1995), and both p53
and Bax have been shown to be important determinants of the
cellular response to chemotherapeutic agents (Bunz et al, 1999;
Zhang et al, 2000). In the extrinsic pathway, however, caspase
activation is initiated by death receptors on the cell surface
(Ashkenazi and Dixit, 1998). Chemotherapeutic agents are known
to induce apoptosis by either of these two mechanisms (Lowe and
Lin, 2000; Johnstone et al, 2002).
While significant progress has been made in the identification of
markers predicting response to 5FU and CPT-11, two additional
chemotherapeutic agents commonly used for colorectal cancer
treatment (Augenlicht et al, 1997; Bunz et al, 1999; Salonga et al,
2000; Arango and Augenlicht, 2001; Arango et al, 2001, 2003), there
is great need for markers that allow discrimination of tumours that
vary in their sensitivity to oxaliplatin. The tumour suppressor p53
has a pivotal role in determining the cellular sensitivity to a
number of chemotherapeutic agents, including 5FU and CPT-11
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y(Bunz et al, 1999; Arango et al, 2001, 2003; Magrini et al, 2002). In
this study we investigated the potential of this genetic marker to
predict response to oxaliplatin in vitro. Previous studies have
shown that simultaneous analysis of multiple independent markers
capable of predicting response to chemotherapy significantly
improves the accuracy of the predictions (Salonga et al, 2000;
Arango et al, 2001). cDNA microarray analysis allows the
assessment of the level of expression of thousands of genes
simultaneously, and its potential to predict response of tumour
cells to chemotherapeutic agents has been recently demonstrated
(Scherf et al, 2000; Kihara et al, 2001; Zembutsu et al, 2002;
Mariadason et al, 2003). Therefore, we hypothesised that the
expression profile of untreated tumour cells could be used to
predict sensitivity to oxaliplatin, and used a leave-one-out cross-
validation approach to formally demonstrate the accuracy of this
approach in a panel of 30 colorectal cancer cell lines.
MATERIALS AND METHODS
Cell culture
HCT116 colon carcinoma cells and isogenic derivatives with a
targeted inactivation of p53 or Bax (Bunz et al, 1998; Zhang et al,
2000) were a gift of Dr Vogelstein (Johns Hopkins University
School of Medicine). Cells were maintained in minimum essential
medium (MEM) supplemented with 10% fetal bovine serum (FBS),
1  antibiotic/antimycotic (100Uml
 1 streptomycin sulphate,
100Uml
 1 penicillin G sodium and 0.25mgml
 1 amphotericin
B), 100mM nonessential amino acids and 10mM HEPES buffer
solution (all from Invitrogen Corporation, Carlsbad, CA, USA).
Cell cycle and apoptosis
For analysis of cell cycle, 2 10
5 HCT116 cells were seeded on six-
well plates in triplicate and allowed to attach for 24h. For time-
response studies cells were treated with 5 or 10mM oxaliplatin
(supplied by Sanofi-Synthelabo, New York, NY, USA) for 12, 24, 48
and 72h. For concentration–response experiments, cells were
treated for 72h with 5, 10, 15, 20, 25 and 50mM oxaliplatin. Both
attached and floating cells were harvested, washed twice with 2ml
of PBS and resuspended in PBS containing 50mgml
 1 propidium
iodine (PI), 0.1% sodium citrate and 0.1% Triton X-100. Cells were
stained overnight at 41C and a minimum of 10000 cells analysed
for DNA content using a Becton Dickinson FACScan (Becton
Dickinson Immunocytometry Systems, San Jose, CA, USA). The
proportion of cells in G0/G1, S phase and G2/M were quantified
using ModFit 2.0 (Verity Software House, Topsahm, ME, USA).
Apoptosis induced by oxaliplatin treatment was assessed by the
nuclear morphology of floating cells. HCT116 cells (1.6 10
6) were
seeded on T75 culture flasks and allowed to attach to the substrate
for 24h before exposure to 25mM oxaliplatin for 48h. Floating cells
were collected, pelleted and re-suspended in 1mM DAPI (Sigma, St
Louis, MO, USA) in PBS. Micrographs of DAPI stained nuclei were
captured with a SPOT RT Diagnostic Instruments CCD camera
(Diagnostic Instruments, Sterling Heights, MI, USA) attached to a
BX60 Olympus fluorescence microscope (Olympus, Melville, NY,
USA). Quantification of apoptosis was carried out by PI staining
and flow cytometric analysis of the proportion of cells with a
subdiploid content of DNA using WinList 2.0 (Verity Software
House, Topsahm, ME, USA). In some experiments, cell cultures
were preincubated with 2mgml
 1 anti-Fas receptor antibody ZB4
(Upstate Biotechnology, Lake Placid, NY, USA) or 1mgml
 1 anti-
Fas ligand antibody NOK-1 (BD Biosciences Pharmingen, San
Diego, CA, USA) for 1h before oxaliplatin cotreatment. Some
HCT116 cultures were coincubated with the pan-Caspase inhibitor
z-VAD-fmk (Calbiochem, La Jolla, CA, USA) at the final
concentrations indicated in the text.
Caspase 3 activation
HCT116 cells (2 10
5) were seeded on six-well plates in triplicate,
allowed to attach for 24h, and then treated with 25mM oxaliplatin.
After 72h of treatment, floating cells were collected and pooled
with the attached cells harvested by trypsinisation. Cells were
washed with PBS, resuspended in CytoFix/CytoPerm (Pharmingen,
San Diego, CA, USA), incubated for 30min on ice and then washed
with Perm/Wash buffer (Pharmingen, San Diego, CA, USA) and
resuspended in 100ml of Perm/Wash buffer. In total, 20mlo f
phycoerythrin (PE)-conjugated anti-active caspase-3 (Pharmingen,
San Diego, CA, USA) were added and cells were incubated at 41Ci n
the dark for 30min, washed with Perm/Wash buffer and
resuspended in 400ml of Perm/Wash buffer. Samples were
analysed using a Becton Dickinson FACScan, measuring logarith-
mic PE fluorescence in the FL-2 channel in a minimum of 10000
cells.
Western blotting
HCT116 cells seeded in 75cm
2 flasks were treated with
10mM oxaliplatin for 0, 6, 12, 16 or 24h and then rinsed with
PBS twice, harvested and resuspended in 300ml of RIPA
lysis buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
0.15 M NaCl, 0.01 M sodium phosphate pH 7.2, 2mM EDTA, 50mM
sodium fluoride, 0.2mM sodium vanadate and 100Uml
 1 aproti-
nin). The cell suspension was vortexed and kept on ice for
30min before cell debris was pelleted and the supernatant
transferred to a new tube. SDS–polyacrylamide gel electrophoresis
sample loading buffer (6 ) was added to 20mg aliquots and
loaded on 15% tris-HCl precast gels (BioRad, Hercules, CA, USA).
Fractionated proteins were transferred to a PVDF membrane
(Amersham, Piscataway, NJ, USA) and blocked with 10%
nonfat milk for 1h. Membranes were then probed at room
temperature with the appropriate primary antibody in 5% nonfat
milk for 1h with the following antibodies: anti-p53 (Santa Cruz,
DO-1, 1/7000), anti-p21
Cip1/WAF1 (Santa Cruz, H-164, 1/200) and
anti-b-actin (Sigma, clone AC74, 1/1000). Membranes were washed
three times with washing buffer (PBS with 0.1% Tween 20)
and then probed with the appropriate peroxidase-conjugated
secondary antibody for 1h (all from Roche Diagnostics/Boehringer
Mannheim Corporation, Indianapolis, IN, USA). The secondary
antibody was washed three times with washing buffer and the
signal was developed using ECL Plus Western Blotting
Detection Method (Amersham, Piscataway, NJ, USA). Detection
was carried out using a Storm PhosphorImager and quantified
using ImageQuant software (Molecular Dynamics, Sunnyvale, CA,
USA). Protein levels were standardised using the signal from the
b-actin probe.
Immunofluorescence analysis
Cells were cultured overnight on preferred glass coverslips (Fisher,
Pittsburgh, PA, USA), and then treated with 10, 20 or 50mM
oxaliplatin. The cells were fixed for 15min in 4% paraformalde-
hyde (Electron Microscopy Services, Ft Washington, PA, USA),
permeabilised with 0.5% Triton X-100/PBS for 5min and then
incubated for 1h in a 1% BSA/PBS blocking solution. To detect
BAX, cells were incubated for 3h with a rabbit polyclonal IgG that
recognised the N-terminal region (Upstate Biotechnology, Lake
Placid, NY, USA; 1:100 dilution), followed by exposure to a goat
Cy3-conjugated anti-rabbit secondary antibody (Amersham, Pis-
cataway, NJ, USA). To detect mitochondria, a mouse monoclonal
Hsp60 antibody was used (Santa Cruz Biotechnology, Santa Cruz,
CA, USA; 1:200), the binding of which was detected by a goat
anti-mouse FITC-conjugated secondary antibody (Roche
Diagnostics/Boehringer Mannheim Corporation, Indianapolis, IN,
USA). Cytochrome c was detected utilising a mouse monoclonal
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followed by exposure to a goat anti-mouse Cy5-conjugated
secondary antibody (Amersham Biosciences, Piscataway, NJ,
USA). All secondary antibodies were used at a dilution of 1:200
for 1h. All washes were performed with PBS. To visualise nuclei,
cells were stained with DAPI (Sigma, St Louis, MO, USA; 40,6-
diamidino-2-phenylindole). Fluorescent images were captured
with a SPOT RT Diagnostic Instruments CCD camera (Diagnostic
Instruments, Sterling Heights, MI, USA) attached to a BX60
Olympus fluorescence microscope (Olympus, Melville, NY, USA).
The proportion of apoptotic cells was quantified by scoring the
number of cells simultaneously exhibiting Bax relocalisation and
cytochrome c release in 200 cells.
Growth/cytotoxicity assay
The concentration of oxaliplatin resulting in 50% inhibition of
control growth (GI50) in response to oxaliplatin was calculated
using the sulphorhodamine B method according to the protocol
used by the NCI in vitro Anticancer Drug Discovery Screen
Program (Skehan et al, 1990). Ten thousand cells per well were
seeded in 96-well plates and 24h later exposed to 0, 0.0125, 0.025,
0.125, 0.25, 1.25, 2.5, 6.25, 12.5, 25, 50 and 125mM oxaliplatin for
72h. The GI50 concentrations were calculated as described (Skehan
et al, 1990; Arango et al, 2003; Mariadason et al, 2003) using Prism
3.0 software (GraphPad, San Diego, CA, USA).
Clonogenic assay
One million cells were seeded in T25 flasks and 24h later exposed
to 0, 2.5, 3, 3.5 or 4mM oxaliplatin for 9h. Cells were then
trypsinised and 500 cells reseeded in six-well plates in triplicate.
Colonies were allowed to form for 2 weeks and then plates were
washed and air-dried. Colonies were stained with 0.1% crystal
violet, washed three times with distilled water, and air-dried. Plates
were scanned using a Perfection 1250 scanner (Epson America
Inc., Long Beach, CA, USA) and the number of colonies quantified
using Total Lab 1.1 software (Nonlinear Dynamics, Durham,
NC, USA).
Assessment of p53 status
The mutational status of the 30 colorectal cancer cell lines in the
panel used has been previously reported (Mariadason et al, 2003).
Sequencing of the hotspots for p53 mutations (exons 5–8) in T84
cells found no mutations (Mariadason et al, 2003). Moreover,
Western blot analysis demonstrated that T84 cells have low basal
p53 levels, which is characteristic of colorectal cancer cells with a
wild-type p53 gene. However, subsequent analyses showed that,
unlike other wild-type p53 cell lines in the panel, T84 cells failed to
upregulate the p53 target gene p21
Waf1/Cip1 in response to cytotoxic
insult (5 and 50mM 5-FU for 24h – not shown). We, therefore,
sequenced the remaining of the p53 coding sequence in this cell
line and found a missense mutation in exon 4 (codon 60, CCA-
CTA; Pro-Leu). Moreover, this mutation has previously been
identified in human malignancies, further suggesting that this
mutation disrupts p53 function (http://p53.curie.fr). The p53
primers used in the PCR reactions were exon 2: CGACTGTCCA
GCTTTGTGC and CCCGTGACTCAGAGAGGACT; exon 2: GGGTT
GGAAGTGTCTCATGC and TCCCACAGGTCTCTGCTAGG; exon
3: CAGTCAGATCCTAGCGTCGAG and AGCCCAACCCTTGTCCT
TAC; exon 4: CCTCTGACTGCTCTTTTCACC and AGAAATGCAG
GGGGATACG; exon 9: GCAGTTATGCCTCAGATTCACT and AA
CTTTCCACTTGATAAGAGGTC; exon 10: GTACTGTGAATATAC
TTACTTCT and CCTATGGCTTTCCAACCTAGGAA; exon 11: TTA
GGCCCTTCAAAGCATTGGT0 and CACCTATTGCAAGCAAGG
GTTCA.
Microarray analysis
The expression profile of the same panel of 30 colorectal
cancer cell lines was assessed in using 9216-sequence
cDNA microarrays from the Albert Einstein Cancer Center
Facility as previously described (Mariadason et al, 2003). For each
cell line, hybridisations were carried out in duplicate starting from
RNA isolated from independent cultures. For each set of replicates,
the mean expression value for each sequence was determined
and entered into a final database for further analyses. The
expression data for the 3725 sequences with a significant level
of expression (defined as signal4background plus two
standard deviations in the Cy5 and/or Cy3 channel) in at
least one replicate for all 30 cell lines was used in subsequent
analyses. All the databases are available on our website (www.au-
genlichtlab.com).
‘Leave-One-Out’ cross-validation analysis
All leave-one-out analyses (Efron and Tibshirani, 1993) were
performed using genes that showed a significant level of
expression above background in each of the 30 cell lines (3725
of the 9216 genes on the arrays). First, from the 30 cell lines, cell
line 1 was removed from consideration, leaving 29 cell lines for
analysis. For these 29 cell lines, the Pearson correlation between
the level of expression of each of the 3725 genes and the percentage
of apoptosis induced by 10mM oxaliplatin was computed, and the N
genes highest absolute value correlations (i.e., corresponding to N
genes) were selected. N was varied from the 10 to 200 best-
correlated genes. As a control, N randomly selected genes were also
analysed. To reduce the number of genes to a smaller set of
variables, principal components analysis (PCA) was performed.
PCA enables a large number of variables to be reduced to linear
combinations of variables that can be used to predict an outcome.
From the PCA, the principal components (PCs) having the 10
largest eigenvalues were selected. In general, these 10 PCs
accounted for approximately 60% of the variance in the selected
genes. Next a multiple regression model was developed using the
10 PCs to predict apoptosis, based on the 29 cell lines in the
analysis. Once the regression equation was derived, the 10 PCs
corresponding to the ‘left out’ cell line were computed and
substituted into the derived regression equation to yield a
prediction of apoptosis in the left out cell line. Thus, the final
results for this first leave-one-out procedure were the predicted
value of apoptosis for the left out cell line (y1*) and the observed
value (y1).
After this first leave-one-out procedure was completed, the left
out cell line was replaced in the data set, and cell line 2 was
removed, once again leaving 29 cell lines in the data set with 1 cell
line left out. The entire procedure was repeated for all 30 cell lines
so that the final result was a set of predicted apoptosis values for
each cell line that had been left out and the corresponding
observed value. Each of these 30 leave-one-out procedures yielded
30 pairs of predicted and observed apoptosis values: y1*, y1, y2*, y2,
y, y30*, y30.
To determine how well a given regression model predicted
observed apoptosis in the left out cell line, the natural log of
observed apoptosis (ln(yi)) was plotted as a function of the
natural log of the predicted value (ln(yi*)), and a simple linear
regression was constructed. The purpose of this regression
analysis was to determine whether the predicted and observed
values obeyed the equation yi¼yi* (i.e., whether the points fall
on the line of equality). If the prediction rule is true, then the
observed and predicted values would be equal or nearly equal.
The measure of linear fit was r, and the hypothesis of falling on the
line of equality was tested by comparing the slope to unity and y
intercept to zero.
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Oxaliplatin induces a G2/M cell cycle arrest and apoptosis
Exposure of an asynchronous culture of HCT116 colon carcinoma
cells to clinically achievable concentrations (Ehrsson et al,
2002; Tassone et al, 2002) of the platinum compound oxaliplatin
resulted in a significant time- and concentration-dependent
accumulation of cells in the G2/M phases of the cell cycle and a
reduction of cells in S phase (Figure 1A–D). These effects of
oxaliplatin on cell cycle progression of proliferating HCT116 cells
were accompanied by a significant proportion of cells showing
signs of an apoptotic death, which was confirmed by the
characteristic morphological changes observed in DAPI-stained
nuclei of oxaliplatin-treated cells (Figure 2A and B). Quantification
of the proportion of apoptotic cells by PI staining and flow
cytometric analysis demonstrated that exposure of HCT116 cells to
clinically achievable concentrations of oxaliplatin resulted in a
significant time-dependent induction of apoptosis (Figures 1A and
2C) and that the proportion of apoptotic cells was concentration-
dependent (Figures 1B and 2D).
The apoptotic cascade initiated by oxaliplatin is
characterised by translocation of Bax to the mitochondria,
cytochrome c release and caspase 3 activation
To investigate the molecular cascade of events following exposure
to oxaliplatin, we utilised HCT116 cells, which have a wild-type
p53 gene and express a functional Bax protein. Immuno-
fluorescent staining of Bax in untreated HCT116 cells demon-
strated a diffuse cytoplasmic localisation of Bax in most cells
(Figure 3A). In agreement with a low incidence (o1%) of
spontaneous apoptosis in untreated cultures (see Figure 2C), a
small proportion of cells showed punctate Bax staining that was
demonstrated to localise to the mitochondria by co-staining
with Hsp60, a heat shock protein with mitochondrial localisation
(Supplementary material Figure 1). However, exposure of HCT116
cells to 10mM oxaliplatin resulted in a significant (Po0.001)
increase in the number of cells that exhibited a mitochondrial
pattern of Bax staining (white arrowheads in Figure 3A).
Translocation of Bax to the mitochondria has been implicated in
the formation of the permeability transition pore and cytochrome
c release from the mitochondria into the cytoplasm (Narita et al,
1998; Gross et al, 1999). Nonapoptotic untreated HCT116 cells
exhibited a mitochondrial localisation of cytochrome c (Figure 3A).
However, oxaliplatin treatment resulted in an increase in the
number of cells showing a diffuse cytoplasmic cytochrome c
immunostaining (yellow arrowheads in Figure 3A). The observed
relocalisation of Bax and cytochrome c following treatment of
HCT116 cells with oxaliplatin was concurrent (Figure 3A) and
time- and concentration-dependent (Figure 3B and C). Extension
of these analyses to other colorectal cancer cell lines showed that
exposure of RKO, RW2982 and SW403 cells to 10, 20 or 50mM
oxaliplatin resulted in a significant (Po0.01) increase in the
number of cells showing Bax/cytochrome c re-localisation
(Figure 3C).
Cytoplasmic cytochrome c has been shown to bind to other
components of the apoptosome, resulting in caspase activation
(Liu et al, 1996; Zou et al, 1997). A time-dependent Caspase 3
activation was demonstrated in oxaliplatin-treated cells by
immunostaining with a fluorescently labelled antibody that binds
specifically to active Caspase 3, and quantified using flow
cytometry (Figure 4A). In agreement with this observation,
treatment of HCT116 cells with oxaliplatin in the presence of
different concentrations of z-VAD-fmk, a pan-caspase inhibitor,
reduced oxaliplatin-induced apoptosis in a concentration-depen-
dent manner (Figure 4B).
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Figure 1 Effects of oxaliplatin on cell cycle. The cell cycle distribution of
HCT116 cells was determined after, (A) exposure to 5mM oxaliplatin for
different times, and (B) treatment for 72h with different concentrations of
oxaliplatin. Representative experiments are shown. In panels (C and D) the
number of cells in G0/G1, S phase and G2/M were quantified by PI staining
and flow cytometric analysis. Mean of three experiments is shown.
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response to oxaliplatin
The cellular translocation of Bax to the mitochondria observed in
HCT116 cells following exposure to oxaliplatin suggested a
functional role for this Bcl2 family member in the apoptotic
cascade initiated by oxaliplatin. To investigate the role of Bax in
oxaliplatin-induced apoptosis, we utilised an isogenic HCT116
derivative line that differs only in the absence of a functional Bax
gene. Propidium iodide (PI) staining and flow cytometric analysis
demonstrated a significant (Po0.03) time- and dose-dependent
reduction in the number of apoptotic cells in HCT116 Bax
 /  cells
compared to isogenic Bax
þ/þ cells following oxaliplatin exposure
(Figure 5A and B). In agreement with this observation, HCT116
Bax
 /  cells treated with 20mM oxaliplatin for 24h showed a
significant (P¼0.03) reduction compared to isogenic Bax
þ/þ cells
in the number of cells with the cytosolic staining pattern of
cytochrome c characteristic of apoptotic cells (Figure 5C), further
demonstrating an important functional role of Bax in oxaliplatin-
induced apoptosis.
Oxaliplatin-induced apoptosis is not dependent upon Fas/
FasL association in HCT116 cells
Bax relocalisation to the mitochondria, accumulation of cyto-
chrome c in the cytoplasm and Caspase 3 activation are all events
consistent with an intrinsic pathway of activation of apoptosis by
oxaliplatin. To investigate the contribution of the extrinsic
pathway in oxaliplatin-induced apoptosis, we used antibodies that
specifically recognise either the Fas receptor (ZB4) or the Fas
ligand (NOK-1) and disrupt Fas/FasL association and the
subsequent induction of apoptosis by this pathway. Preincubation
of HCT116 cells with either ZB4 or NOK-1 antibodies was effective
in preventing apoptosis induced by recombinant human soluble
Fas ligand (rhFasL; Figure 6A). However, pretreatment with ZB4 or
NOK-1 antibodies did not affect apoptosis induced by oxaliplatin
(Figure 6A), suggesting that this extrinsic pathway of induction of
apoptosis was not activated by oxaliplatin in HCT116 cells.
Role of p53 in the response to oxaliplatin
More than 50% of colonic tumours have a mutant p53 gene (Baker
et al, 1990), and a functional p53 protein has been shown to be
important for the cellular response to a variety of proapoptotic
stimuli, including chemotherapeutic agents commonly used in the
treatment of colorectal cancer, such as 5FU and CPT-11 (Bunz et al,
1999; Arango et al, 2001, 2003; Magrini et al, 2002). Here, we
demonstrate that exposure of wild-type p53 HCT116 cells to
oxaliplatin results in increased levels of p53 (Figure 6B), and
consistent with this observation, the p53 target gene p21
waf1/cip1
was also upregulated (Figure 6B). The product of the p53 gene is a
transcription factor that can either promote apoptosis, through
different mechanisms such as Bax upregulation, or induce cell
cycle arrest and DNA damage repair by means of the transcrip-
tional upregulation of genes such as p21
waf1/cip1 and Gadd45.
Therefore, we directly tested the role of p53 in the sensitivity of
colon cancer cells to oxaliplatin using parental wild-type p53
HCT116 cells and isogenic HCT116 p53
 /  cells. Relative to
parental cells, p53-deficient HCT116 cells showed a time- and
concentration-dependent protection from the apoptotic effects of
oxaliplatin (Figure 7A and B). The reduced apoptotic effects of
oxaliplatin in HCT116 p53
 /  could be detected after 16h of
treatment as a 10-fold reduction in the number of cells exhibiting
Bax translocation and cytochrome c release compared to parental
HCT116 p53
þ/þ (not shown). Moreover, the concentration of
oxaliplatin necessary to cause a 50% growth inhibition (GI50) after
72h of exposure was four-fold higher in HCT116 p53
 /  cells
compared to parental HCT116 cells (2.0470.15 and 0.5370.04mM
respectively; Po0.0001; Figure 7C). To investigate the long-term
implications of the reduced apoptosis and growth inhibition in
response to oxaliplatin in HCT116 p53
 /  cells, we assessed the
clonogenic potential of parental HCT116 p53
þ/þ and isogenic
HCT116 p53
 /  cells 2 weeks after exposure to oxaliplatin for 9h.
This assay demonstrated that exposure of parental HCT116 p53
þ/þ
cells to concentrations of oxaliplatin ranging from 2.5 to 4mM,
resulted in up to 70% reduction in the number of cells with long-
term clonogenic potential. In contrast, these concentrations of
oxaliplatin had no effect on clonogenicity of HCT116 p53
 /  cells
(Figure 7D), further demonstrating that inactivation of p53 in
colon cancer cells results in a significant protection from
oxaliplatin cytotoxicity.
To further investigate the role of p53 in the response of
colorectal cancer cells to oxaliplatin, we assessed the sensitivity to
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Figure 2 Induction of apoptosis by oxaliplatin. (A) Nuclear morphology
of DAPI stained untreated HCT116 cells and (B) floating cells from cultures
treated with 10mM oxaliplatin for 48h. The number of apoptotic cells was
quantified by PI staining and flow cytometric analysis in cultures treated with
5o r1 0 mM oxaliplatin for different times (C) and with different
concentrations after 72h of treatment (D). Mean of three experi-
ments7s.e. of the mean is shown in (C and D). *Po0.05 and **Po0.005
(Student’s t-test).
Sensitivity of colorectal cancer cells to oxaliplatin
D Arango et al
1935
British Journal of Cancer (2004) 91(11), 1931–1946 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ythis agent in a panel of 30 different colorectal cancer cell lines of
known p53 mutational status (Mariadason et al, 2003). Of these 30
cell lines, 11 had a wild-type p53 gene, and the remaining 19
exhibited inactivating mutations in this tumour suppressor.
Considerable variability was observed among different colorectal
cancer cell lines in the number of apoptotic cells following 72h
treatment with 10mM oxaliplatin (Figure 8A). Despite the clear role
of p53 in the apoptotic response to oxaliplatin demonstrated using
the HCT116 isogenic system that differs only in the presence or
absence of a functional p53 protein, the mutational status of this
HCT116 RKO RW2982 SW403
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Figure 3 Oxaliplatin induced apoptosis is characterised by Bax relocalisation and cytochrome c release. (A) Immunofluorescent staining with a Bax
antibody demonstrating diffuse cytoplasmic staining in the majority of the cells in untreated cultures is shown. Exposure to 10mM oxaliplatin for 24h resulted
in a significant proportion of cells exhibiting punctate Bax staining (white arrowheads) consistent with its mitochondrial localisation (see Results).
Cytochrome c was confined to the mitochondria in the majority of untreated cells. Oxaliplatin treatment resulted in a significant increase in the number of
cells displaying a diffuse cytosolic staining of cytochrome c (yellow arrowheads). (B) Fold induction in the number of cells exhibiting simultaneous Bax
relocalisation and cytochrome c release in cultures treated with 50mM oxaliplatin for various times (mean of at least two experiments7s.e.). (C) Treatment
of HCT116, RKO, RW2982 and SW403 cells with different concentrations of oxaliplatin for 24h resulted in a significant concentration-dependent increase
in the number of cells showing Bax and cytochrome c re-localisation. *Po0.01 (Student’s t-test).
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ytumour suppressor gene could not predict the apoptotic response
to 10mM oxaliplatin (Figure 8A), suggesting that additional factors
modulate sensitivity to this agent.
Response to oxaliplatin can be predicted using the
expression profile of untreated colorectal cancer cells
Due to the great complexity of the molecular mechanisms
determining response to oxaliplatin, analysis of the p53 mutational
status is likely to be of limited predictive value in the clinical
setting. As an alternative approach, we used cDNA microarray
analysis to assess the levels of expression of 9216 sequences in the
same panel of 30 colorectal cancer cell lines, and used the
expression profile of untreated cells to make predictions concern-
ing response to oxaliplatin.
In order to validate the accuracy of the predictions within the
panel of 30 cell lines we used a ‘leave-one-out’ cross-validation
approach. Here, one of the 30 samples is held out, and the N genes
whose expression best correlates with the apoptotic response are
selected using the remaining 29 cell lines. The apoptotic response
in the 30th line is then estimated using the expression of those N
genes and a predictor based on a multiple regression model (see
Materials and Methods for details). This process is repeated 30
times holding out a different cell line in each iteration. In this way,
a predicted value for the apoptotic response to oxaliplatin is
obtained for each of the 30 cell lines, which can then be compared
to the experimentally observed response to this agent. To optimise
the predictive rule, we tested the effect of varying the number of N
input genes from the 10-best through 200-best correlated with
oxaliplatin-induced apoptosis (see Materials and Methods). This
analysis demonstrated that selection of the 80 genes best correlated
with oxaliplatin-induced apoptosis produced the most accurate
prediction, with a highly significant correlation (r¼0.53,
P¼0.002) between the observed and estimated response to
oxaliplatin (Figure 8B). Importantly, the correlation between
observed and estimated response to oxaliplatin by a group of 80
randomly selected genes was not significant (P¼0.19). This
formally demonstrates that cDNA microarray based expression
profiling can be used to predict response to oxaliplatin in
colorectal cancer cells.
The ‘leave-one-out’ cross-validation approach adopted pro-
duced a slightly different list of 80 genes in each iteration, as a
different cell line is held out in each round of analysis. A total of
254 genes were used in at least one of the 30 cycles, and 28 of them
were present in all of the 30 gene lists used (Table 1). The
expression profile of all 9216 genes in the cDNA microarrays used
can be found on our website (www.augenlichtlab.com).
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Figure 5 Role of Bax in sensitivity of colon cancer cells to oxaliplatin. (A)
Percentage of apoptotic cells following exposure of HCT116 Bax
þ/þ and
Bax
 /  to the indicated concentrations of oxaliplatin for 72h is shown. (B)
Induction of apoptosis in isogenic Bax proficient and deficient HCT116 cells
after exposure to 20mM oxaliplatin at various times is shown. (C) Number
of cells with a cytoplasmic cytochrome c staining pattern (per 200 cells)
following exposure to 20mM oxaliplatin for 24h. In all cases, the mean of
three experiments7s.e. of the mean is shown. *Po0.05; **Po0.01
(Student’s t-test).
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The platinum compound oxaliplatin is frequently used in the
treatment of colorectal cancer patients that are resistant to 5FU,
and can also be used in combination with 5FU or CPT-11,
improving response rates and progression-free survival (Levi et al,
1993; Bertheault-Cvitkovic et al, 1996; Machover et al, 1996; de
Gramont et al, 1997, 2000; Andre et al, 1999; Maindrault-Goebel
et al, 1999; Giacchetti et al, 2000). Oxaliplatin disrupts DNA
replication and transcription by forming intrastrand DNA adducts,
but the downstream molecular events underlying the cytotoxic
effects of this chemotherapeutic agent have not been well
characterised.
Here, we show that exposure of HCT116 colon cancer cells to
clinically relevant concentrations of oxaliplatin (Ehrsson et al,
2002; Tassone et al, 2002) greatly reduced the long-term
clonogenic potential of these cells (solid line in Figure 7D). This
was associated with an arrest of proliferating cells in the G2/M
phases of the cell cycle (Figure 1). Consistent with this observation,
there was a significant reduction in the growth rate of oxaliplatin-
treated cells compared to control untreated cells (solid line in
Figure 7C). Importantly, exposure of HCT116 cells to oxaliplatin
resulted in a significant induction of apoptosis detectable as early
as 24h after treatment with the lowest concentration assessed (see
Figure 2C). Although impairment of the growth of tumour cells is
an important component contributing to the overall response to
chemotherapy, cell death is the preferred method of elimination of
malignant cells, since this is a terminal and irreversible mechan-
ism. Clonal selection of tumour cells frequently results in the
acquisition of mechanisms of evading apoptosis. Therefore,
understanding of the molecular mechanisms involved in the
induction of apoptosis after exposure to chemotherapeutic agents
is important for two reasons: first, it can provide information
regarding pathways that may be modulated to improve treatment
efficacy, and second, it can lead to the identification of markers
capable of predicting the probability of response to treatment.
In this study we demonstrate that exposure of four different
colorectal cancer cells (HCT116, RKO, RW2982 and SW403) to
oxaliplatin resulted in recruitment of Bax to the mitochondria,
release of cytochrome c to the cytosol and Caspase 3 activation.
Targeted inactivation of Bax in HCT116 cells resulted in a
significant reduction in the number of cells displaying a cytosolic
staining pattern of cytochrome c and terminal apoptosis following
exposure to oxaliplatin. These results demonstrated an important
functional role of Bax in the apoptotic cascade of events initiated
by exposure to oxaliplatin and are in agreement with previous
reports (Gourdier et al, 2002; Hayward et al, 2004). Moreover, it
has been suggested that frameshift mutations in the G8 track of the
Bax gene could contribute to the acquisition of resistance to
oxaliplatin in HCT116 cells (Gourdier et al., 2002). Collectively,
these observations suggest the potential of Bax as a genetic marker
capable of predicting the probability of response of colorectal
cancer patients to this important chemotherapeutic agent.
Bax relocalisation to the mitochondria, release of cytochrome c
to the cytosol and Caspase 3 activation, are all events consistent
with the induction of an intrinsic apoptotic pathway, characterised
by the central role of the mitochondria in the initiation of the
caspase cascade. Some chemotherapeutic agents, however, induce
an apoptotic response through activation of the extrinsic pathway
by promoting Fas receptor/Fas ligand association, which in turn
leads to the formation of the death-inducing signaling complex
(DISC) and the autocatalytic activation of pro-caspase 8. To
investigate the contribution of this pathway to oxaliplatin-induced
apoptosis, we utilised antibodies that bind to Fas or FasL, thus
preventing the association of these two proteins. Although
abrogation of Fas/FasL association completely prevented apoptosis
induced by recombinant human Fas ligand, it had no effect on
oxaliplatin-induced apoptosis, suggesting the predominance of the
intrinsic pathway in the apoptotic program initiated by oxaliplatin
exposure in HCT116. However, Marchetti et al (2004) have recently
demonstrated the involvement of the extrinsic pathway in
oxaliplatin-induced apoptosis in HCT15 colon cancer cells,
suggesting that the role of this pathway may be tumour dependent.
Considerable progress has been made in the identification of
genetic markers allowing prediction of colorectal cancer response
to 5-FU and CPT-11, which together with oxaliplatin are
commonly used for the treatment of these patients (Augenlicht
et al, 1997; Bunz et al, 1999; Salonga et al, 2000; Arango and
Augenlicht, 2001; Arango et al, 2001, 2003). However, despite
recent efforts (Arnould et al, 2003; Rakitina et al, 2003) it is
currently not possible to accurately predict response to oxaliplatin.
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Figure 6 (A) Role of Fas/FasL association in oxaliplatin-induced
apoptosis. Exposure of HCT116 to either recombinant human Fas ligand
(rhFasL) or oxaliplatin resulted in significant induction of apoptosis.
Preincubation with antibodies that prevent Fas/FasL association (ZB4 or
NOK-1) for 1h prevented apoptosis induced by rhFasL but had no effects
on oxaliplatin-induced apoptosis. Mean of three experiments7s.e. (B)
Effects of oxaliplatin treatment in p53 levels. Western blot analysis
demonstrated that exposure of HCT116 cells to 10mM oxaliplatin results in
increased levels of p53 and the cdk inhibitor p21
waf1/cip1, a p53 target gene.
b-Actin levels on a parallel blot are shown as a loading control.
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yp53 is mutated in over 50% of colorectal tumours, and the
mutational status of this tumour suppressor has been shown to
increase or decrease tumour sensitivity to a number of chemother-
apeutic agents. Here we show that oxaliplatin-induced apoptosis
was associated with upregulation of p53 protein levels, detectable
within 6h of treatment. This suggested a role of p53 in the
apoptotic cascade initiated by oxaliplatin. Using an isogenic
system we showed that targeted inactivation of p53 resulted in a
four-fold increase in the GI50, reduced apoptosis and induced a
significant increase in clonogenic potential after exposure to
oxaliplatin, demonstrating that inactivation of p53 can lead to
significantly increased resistance to oxaliplatin.
However, there are some reports showing that p53 inactivation
does not lead to increased resistance to oxaliplatin (Seo et al, 2002;
Petit et al, 2003), suggesting that the role of p53 in the cellular
response to oxaliplatin may be tumour dependent. To further
investigate the role of p53 in sensitivity of colorectal cancer cells to
oxaliplatin, we used a panel of 30 different cell lines of known p53
mutational status. We measured the induction of apoptosis
following exposure of these 30 cell lines to clinically achievable
doses of oxaliplatin, and found that cell lines with a wild type and
mutant p53 gene did not significantly differ in their apoptotic
response to oxaliplatin (see Figure 8A). Similar disparities have
been reported for the role of p53 in 5FU response, depending upon
whether isogenic cell lines or panels of colorectal cell lines were
studied (Yang et al, 1996; Bunz et al, 1999; Violette et al, 2002).
Therefore, despite the clear role of p53 in the response of colon
cancer cells to oxaliplatin demonstrated using the HCT116 isogenic
system, the multiple genetic and epigenetic differences that exist
between tumours are likely to affect numerous pathways, thus
modulating sensitivity to oxaliplatin. This could limit the clinical
value of p53 and other single markers of response to treatment.
Simultaneous analysis of several independent markers predict-
ing response to drug treatment has been shown to be advantageous
over single markers (Salonga et al, 2000; Arango et al, 2001).
Microarray analysis provides the means of assessing the levels of
expression of thousands of genes simultaneously, and we and
others have recently demonstrated that the expression profile of
untreated tumour cells can be used to predict response of tumour
cells to different chemotherapeutic agents in vitro and in vivo
(Scherf et al, 2000; Kihara et al, 2001; Zembutsu et al, 2002;
Mariadason et al, 2003). Here, we used a cDNA microarray-based
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Figure 7 Role of p53 in sensitivity of colon cancer cells to oxaliplatin. (A) Fold induction of apoptosis in HCT116 p53
þ/þ and HCT116 p53
 /  cultures
after exposure to 25mM oxaliplatin for different times, or (B) to different concentrations oxaliplatin for 72h are shown. (C) Comparison of oxaliplatin-
induced growth inhibition between HCT116 p53
þ/þ and p53
 /  cells. (D) Clonogenic potential of HCT116 p53
þ/þ and p53
 /  cells treated with 2.5–
4mM oxaliplatin for 9h. Values shown are the mean of at least three different experiments7s.e. of the mean.
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panel of 30 colorectal cancer cell lines for which the sensitivity to
oxaliplatin was also assessed. The profile of expression of the 80
genes best correlated with sensitivity was used to predict the
quantitative apoptotic response to oxaliplatin in these 30 cell lines.
Using a ‘leave-one-out’ cross-validation approach we demon-
strated a highly significant correlation between experimentally
observed and microarray-predicted apoptotic response to oxali-
platin (R¼0.53, P¼0.002).
Our microarray experiments identified a number of genes and
expressed sequence tags (ESTs) that are differentially expressed in
cell lines that are sensitive and resistant to oxaliplatin. Among the
254 transcripts that were used in at least one of the 30 ‘leave-one-
out’ cross-validation loops, several of them have a known role in
apoptosis (Table 1). The serine/threonine kinase Protein Kinase C
alpha (PKCa) has been associated with cell survival and the
suppression of apoptosis (Deacon et al, 1997; Orlandi et al, 2003).
PKCa was represented twice in our cDNA microarray and both
probes demonstrated that expression levels were lower in cell lines
with a higher apoptotic response to oxaliplatin. This is in good
agreement with previous reports demonstrating that PKCa levels
modulate the cellular response to cisplatin and oxaliplatin
(Johnson et al, 2002; Orlandi et al, 2003). The transcription factor
NFkB has been shown to be frequently deregulated in colorectal
tumours, and it is associated with increased proliferation and
resistance to apoptosis induced by chemotherapeutic agents (Garg
and Aggarwal, 2002; Orlowski and Baldwin, 2002). Here we found
that the NFkB inhibitor epsilon (NFKBIE) is expressed at higher
levels in the more sensitive cell lines. This is consistent with a
recent report showing that donwregulation of the transcriptional
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Figure 8 Microarray-based prediction of response to oxaliplatin. (A) Percentage of apoptotic cells following exposure of a panel of 30 colorectal cancer
cell lines to 10mM oxaliplatin for 72h. Cell lines with a wild-type p53 gene are indicated (WT). The inset shows the mean percentage apoptosis in p53 wild
type and mutant cell lines. Mean of three independent experiments in triplicate7s.e. of the mean is shown. (B) Correlation between experimentally
observed and expression profile predicted percentage apoptosis following treatment with 10mM oxaliplatin for 72h. The predicted apoptosis value for all 30
cell lines was calculated using the expression profile of the 80 genes best correlated with drug response and a multiple regression model through a leave-
one-out cross-validation approach (see Material and Methods).
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yTable 1 List of 254 genes used at least once in the 30 leave-one-out cross-validation loops
Accession Name Correlation
a
Count in
LOOCV
b Biological process (GO)
c
AA455003 General transcription factor IIH, polypeptide 1, 62kDa  0.77 30 DNA repair
R98008 Progestin and adipoQ receptor family member III  0.70 30 Biological process unknown
AA417012 Zinc-finger protein 336  0.67 30 Regulation of transcription, DNA-dependent
AA412691 Nuclear transcription factor Y, alpha  0.67 30 Regulation of transcription, DNA-dependent
AA030029 Protein kinase C, alpha  0.65 30 Regulation of cell cycle
R06567 Clone 23907 mRNA sequence  0.64 30 Biological process unknown
AA521025 G protein pathway suppressor 1  0.62 30 JNK cascade
AA405769 Phosphoenolpyruvate carboxykinase 1 (soluble)  0.62 30 Gluconeogenesis
AA608576 Microtubule-associated protein, RP/EB family, member 2  0.62 30 Cell proliferation
AA083385 BTB (POZ) domain containing 1  0.62 30 Biological process unknown
W32660 RAP2A, member of RAS oncogene family  0.61 30 Signal transduction
R46662 RAP2A, member of RAS oncogene family  0.61 30 Signal transduction
H14343 Cell division cycle 25B  0.60 30 M phase of mitotic cell cycle
AA480071 Transcription factor 7 (T-cell specific, HMG-box)  0.60 29 Wnt receptor signaling pathway
AA456014 Hypothetical protein FLJ20580  0.60 30 Biological process unknown
H09906 20,30-cyclic nucleotide 30 phosphodiesterase  0.60 30 Synaptic transmission
N51260 KIAA0240  0.60 29 Biological process unknown
H56069 Glutamate–cysteine ligase, catalytic subunit  0.59 30 Cysteine metabolism
AA489104 Thyroid hormone receptor interactor 3  0.59 29 Regulation of transcription, DNA-dependent
T77959 Tripeptidyl peptidase II  0.59 29 Proteolysis and peptidolysis
AA479196 General transcription factor IIF, polypeptide 2, 30kDa  0.59 30 Transcription initiation from Pol II promoter
AA430656 Docking protein 4  0.58 29 Biological process unknown
H30688 Spectrin, beta, nonerythrocytic 2  0.58 29 Vesicle-mediated transport
R10570 Hypothetical protein KIAA1434  0.58 28 Biological process unknown
R54358 Ligase IV, DNA, ATP-dependent  0.57 27 DNA repair
H08548 ATP citrate lyase  0.57 27 Coenzyme A biosynthesis
AA418811 Fibrillin 1 (Marfan syndrome)  0.57 26 Skeletal development
AA410591 Met proto-oncogene (hepatocyte growth factor receptor)  0.57 28 Cell proliferation
W86653 FK506-binding protein 5  0.56 27 Protein folding
H11501 Hypothetical protein BC017169  0.56 27 Transport
AA521490 Limkain b1  0.56 27 Biological process unknown
AA447691 Pitrilysin metalloproteinase 1  0.56 27 Activation of MAP/ERK kinase kinase
R42187 ESTs  0.56 27 Biological process unknown
H89996 CCCTC-binding factor (zinc-finger protein)  0.56 27 Negative regulation of cell cycle
AA148536 Nucleoporin 98kDa  0.56 25 Intracellular protein transport
R01323 Microfibrillar-associated protein 1  0.56 25 Biological process unknown
AA425401 Serine/threonine kinase 24 (STE20 homolog, yeast)  0.55 25 Signal transduction
T49159 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2  0.55 24 Antiapoptosis
AA001918 ESTs  0.55 24 Biological process unknown
N70759 KIAA0996 protein  0.55 24 Biological process unknown
AA232979 Zinc-finger RNA binding protein  0.55 19 Biological process unknown
AA521232 ras-related C3 botulinum toxin substrate 2  0.55 20 Small GTPase mediated signal transduction
AA426311 Mesenchyme homeo box 1  0.55 21 Development
AA074666 ESTs  0.54 15 Biological process unknown
AA479888 Rabaptin, RAB GTPase binding effector protein 1  0.54 14 Endocytosis
AA701929 Bystin-like  0.54 15 Cell adhesion
AA479771 KIAA0076  0.54 19 Biological process unknown
R76314 ras homolog gene family, member G (rho G)  0.54 15 Positive regulation of cell proliferation
AA004484 F-box only protein 9  0.54 17 Protein modification
AA458840 Cell death-regulatory protein GRIM19  0.54 9 Apoptosis
AA036974 Amine oxidase, copper containing 3  0.54 9 Amine metabolism
R28280 Solute carrier family 7, member 1  0.54 10 Amino acid metabolism
AA045192 Retinoblastoma 1 (including osteosarcoma)  0.53 8 Negative regulation of cell cycle
H99215 Discs, large homolog 3 (neuroendocrine-dlg, Drosophila)  0.53 10 Negative regulation of cell proliferation
T71757 Heme oxygenase (decycling) 1  0.53 6 Heme oxidation
AA453175 Bridging integrator 1  0.53 7 Negative regulation of cell cycle
R12275 Hypothetical protein FLJ21827  0.53 6 Biological process unknown
AA478524 M-phase phosphoprotein 6  0.53 7 M phase of mitotic cell cycle
AA434342 Proline arginine-rich end leucine-rich repeat protein  0.53 6 Skeletal development
AA459266 Postmeiotic segregation increased 2-like 6  0.53 5 Mismatch repair
H49592 Guanine nucleotide binding protein (G protein), alpha activating activity
polypeptide
 0.53 7 G-protein coupled receptor protein signaling
pathway
R99749 B-cell CLL/lymphoma 6 (zinc-finger protein 51)  0.53 7 Cell growth and/or maintenance
AA621031 KIAA0056 protein  0.53 7 Biological process unknown
AA232647 Zinc-finger protein 161  0.52 5 Regulation of transcription from Pol II
promoter
AA485214 Nucleobindin 2  0.52 5 Biological process unknown
AA458973 Polymerase (DNA-directed), delta interacting protein 3  0.52 3 Biological process unknown
AA608730 HBS1-like (S. cerevisiae)  0.52 3 Protein biosynthesis
H98688 ESTs  0.52 4 Biological process unknown
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c
AA425908 ADP-ribosylation factor interacting protein 2 (arfaptin 2)  0.52 3 Small GTPase mediated signal transduction
AA424937 Protein kinase C, alpha  0.52 4 Regulation of cell cycle
AA017042 HIV-1 Tat interactive protein, 60kDa  0.52 3 Regulation of transcription, DNA-dependent
AA284338 Chromobox homolog 5 (HP1 alpha homolog, Drosophila)  0.51 2 Chromatin assembly
AA040170 Chemokine (C-C motif) ligand 7  0.51 3 Antimicrobial humoral response
AA425089 Clock homolog (mouse)  0.51 4 Circadian rhythm
N58136 Similar to KIAA0393 protein  0.51 2 Biological process unknown
R24543 Neuroepithelial cell transforming gene 1  0.51 2 Regulation of cell growth
R15708 Insulin-like 4 (placenta)  0.51 2 Cell proliferation
W47073 Solute carrier family 20 (phosphate transporter), member 1  0.51 3 Phosphate transport
AA703187 Solute carrier family 33 (acetyl-CoA transporter), member 1  0.51 4 Transport
W79444 UBX domain containing 2  0.51 2 Biological process unknown
R35292 Growth arrest-specific 2 like 1  0.51 3 Cell cycle arrest
AA406027 CD5 antigen (p56-62)  0.51 2 Cell proliferation
W06875 Hypothetical protein MGC14816  0.51 2 Biological process unknown
R14855 F-box only protein 34  0.50 2 Biological process unknown
R01451 Hypothetical protein KIAA1259  0.50 1 Biological process unknown
AA449154 Skeletal muscle and kidney enriched inositol phosphatase  0.50 2 Actin cytoskeleton organization and
biogenesis
H48420 Prothymosin alpha  0.50 1 Biological process unknown
AA455043 Holocarboxylase synthetase  0.50 2 Protein modification
AA232647 Zinc-finger protein 161  0.50 2 Regulation of transcription from Pol II
promoter
R11490 Translocated promoter region (to activated MET oncogene)  0.50 2 Transport
T58146 HLA complex P5  0.50 2 Defense response
H54366 KIAA0034 gene, complete cds  0.50 2 Biological process unknown
AA406269 Nuclear factor I/X (CCAAT-binding transcription factor)  0.50 2 DNA replication
R02346 Small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen)  0.50 1 RNA splicing
H64850 Clone 23612 mRNA sequence  0.50 1 Biological process unknown
N74574 Hypothetical protein MGC9084  0.49 3 Biological process unknown
N26645 Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease,
Watson disease)
 0.49 2 RAS protein signal transduction
R26434 Protein phosphatase 1, catalytic subunit, beta isoform  0.49 1 Biological process unknown
AA025850 Myosin VA (heavy polypeptide 12, myoxin)  0.49 1 Transport
H59208 ESTs  0.49 1 Biological process unknown
AA490721 Splicing factor, arginine/serine-rich 9  0.49 2 mRNA splice site selection
R10604 Spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, autosomal
dominant, ataxin 2)
 0.49 1 mRNA splicing
R95732 DNA (cytosine-5-)-methyltransferase 2  0.49 1 DNA methylation
AA149096 Hemopoietic cell kinase  0.49 2 Biological process unknown
AA489714 Chromosome 9 open reading frame 60  0.49 1 Biological process unknown
AA045587 TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated
factor, 20kDa
 0.49 2 Regulation of transcription, DNA-dependent
AA485443 Ring finger protein 41  0.48 1 Biological process unknown
AA085676 ADP-ribosylation factor guanine nucleotide factor 6  0.48 1 Biological process unknown
W58032 Frizzled-related protein  0.48 1 Wnt receptor signaling pathway
N71653 Aspartoacylase (aminoacylase 2, Canavan disease)  0.48 2 Aspartate catabolism
AA004324 Hypothetical protein BC007706  0.48 1 Biological process unknown
AA441935 Achaete-scute complex-like 1 (Drosophila)  0.48 1 Cell differentiation
R22050 Topoisomerase (DNA) II beta (180kD)  0.48 1 DNA topological change
W31074 Fatty-acid-Coenzyme A ligase, long-chain 3  0.48 3 Fatty acid metabolism
T72581 Matrix metalloproteinase 9  0.48 3 Collagen catabolism
AA453105 Histone 1, H2ac  0.48 1 Nucleosome assembly
AA988746 WD repeat and SOCS box containing protein 2  0.48 1 Intracellular signaling cascade
AA495766 Chromosome condensation 1-like  0.48 1 Biological process unknown
AA489699 COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis)  0.48 1 Biological process unknown
T65902 Splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing
factor)
 0.48 1 mRNA splice site selection
AA446908 Kinesin family member 3C  0.47 1 Biological process unknown
AA047812 Origin recognition complex, subunit 2-like (yeast)  0.47 1 DNA replication
AA452566 Peroxisomal membrane protein 3, 35kDa (Zellweger syndrome)  0.47 1 Peroxisome organization and biogenesis
R91948 Pantothenate kinase 3  0.47 1 Coenzyme A biosynthesis
T52894 Myosin light chain 1 slow a  0.47 1 Muscle development
AA001749 Microtubule-associated protein, RP/EB family, member 1  0.47 1 Cell proliferation
AA430035 Reticulon 3  0.47 1 Biological process unknown
N79179 Pyruvate dehydrogenase complex, lipoyl-containing component X; E3-
binding protein
 0.47 1 Biological process unknown
R13911 T54 protein  0.47 1 Biological process unknown
AA447579 Hypothetical protein FLJ11101  0.47 1 Biological process unknown
AA454639 F-box only protein 9  0.47 1 Protein modification
Sensitivity of colorectal cancer cells to oxaliplatin
D Arango et al
1942
British Journal of Cancer (2004) 91(11), 1931–1946 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yTable 1 (Continued)
Accession Name Correlation
a
Count in
LOOCV
b Biological process (GO)
c
AA476460 Protein tyrosine phosphatase, receptor-type, Z polypeptide 1  0.46 2 One-carbon compound metabolism
AA147642 cDNA: FLJ21949 fis, clone HEP04922  0.46 1 Biological process unknown
AA479954 Similar to RNA polymerase B transcription factor 3  0.46 1 Biological process unknown
N80382 Phosphodiesterase 6D, cGMP-specific, rod, delta  0.46 1 Visual perception
R88246 Adrenergic, beta, receptor kinase 1  0.45 1 Signal transduction
AA150895 Hypothetical protein MGC26690  0.45 1 Biological process unknown
AA680407 Similar to ubiquitin binding protein  0.45 1 Biological process unknown
AA063398 Chromosome 15 open reading frame 15  0.45 1 Protein biosynthesis
AA459572 Protein phosphatase 1, regulatory subunit 7  0.45 1 Biological process unknown
AA401429 Dynein light chain 2  0.45 2 Microtubule-based process
AA434130 Thioredoxin reductase 2  0.44 1 Response to oxygen radicals
AA453593 BB1¼malignant cell expression-enhanced gene/tumor progression-
enhanced gene
 0.44 1 Protein arginylation
T77891 ESTs  0.44 1 Biological process unknown
N48137 Glycophorin E  0.44 1 Biological process unknown
N30147 CDNA FLJ34899 fis, clone NT2NE2018594.  0.43 1 Biological process unknown
AA011185 Hypothetical protein FLJ14431  0.43 1 Metabolism
N58558 Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 4
 0.43 1 Acute-phase response
AA055221 Apoptosis, caspase activation inhibitor  0.43 1 Apoptosis
AA280677 Zinc-finger protein 258  0.43 1 Development
AA026709 Dedicator of cytokinesis 6  0.43 1 Biological process unknown
AA487070 Similar to CGI-55 protein (LOC152502), mRNA  0.43 1 Biological process unknown
AA284282 Hypothetical protein FLJ30277  0.43 1 Biological process unknown
T57859 Natural killer cell group 7 sequence  0.42 1 Biological process unknown
AA448001 TBP-like 1  0.42 1 Regulation of transcription
N92085 ESTs  0.41 1 Biological process unknown
AA423867 Multimerin  0.41 1 Blood coagulation
AA443302 ras homolog gene family, member E  0.38 1 Small GTPase mediated signal transduction
H52361 ESTs  0.37 1 Biological process unknown
AA482198 Mannose phosphate isomerase  0.36 1 Carbohydrate metabolism
H66030 Centrosomal protein 1  0.36 1 Biological process unknown
AA458472 Major histocompatibility complex, class II, DQ beta 1  0.36 1 Immune response
AA447696 Yippee protein  0.35 1 Biological process unknown
AA419164 Retinoic acid receptor, beta  0.34 1 Cell growth and/or maintenance
AA453849 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b,
isoform 1
 0.32 1 ATP synthesis coupled proton transport
T96688 PBX/knotted 1 hoemobox 1  0.32 1 Biological process unknown
R41732 Mitogen-activated protein kinase 8 interacting protein 1 0.28 1 Vesicle-mediated transport
AA419622 Hypothetical protein FLJ10134 0.31 1 Biological process unknown
AA128017 Clone DNA100312 VSSW1971 (UNQ1971) mRNA 0.33 1 Biological process unknown
R23810 Full-length insert cDNA YI09H09 0.33 1 Biological process unknown
T90871 EST 0.35 1 Biological process unknown
AA005228 ESTs 0.39 1 Biological process unknown
AA004811 ESTs 0.39 1 Biological process unknown
R54797 ESTs, Weakly similar to reverse transcriptase homolog 0.39 1 Biological process unknown
T95930 ESTs 0.40 1 Biological process unknown
AA058713 ESTs 0.41 1 Biological process unknown
T84865 ESTs 0.41 1 Biological process unknown
N46943 GGA binding partner 0.41 1 Biological process unknown
AA677403 Glycoprotein hormones, alpha polypeptide 0.42 1 Cell–cell signaling
AA872379 SMT3 suppressor of mif two 3 homolog 1 (yeast) 0.42 1 Biological process unknown
T96870 ESTs 0.42 1 Biological process unknown
AA610111 Hypothetical protein FLJ21868 0.43 1 Biological process unknown
AA400121 A-kinase anchoring protein 28 0.44 1 Biological process unknown
H72319 ESTs 0.44 1 Biological process unknown
H23124 Olfactomedin related ER localized protein 0.44 1 Biological process unknown
AA447515 MAX dimerization protein 4 0.44 1 Negative regulation of cell proliferation
N62914 EST 0.44 1 Biological process unknown
T53298 Insulin-like growth factor binding protein 7 0.45 1 Negative regulation of cell proliferation
AA421488 CDNA FLJ26472 fis, clone KDN04506 0.46 1 Biological process unknown
H93837 Apolipoprotein B (including Ag(x) antigen) 0.46 1 Lipid transport
N78306 ESTs 0.46 1 Biological process unknown
N32502 ESTs 0.46 1 Biological process unknown
AA488672 Kruppel-like factor 7 (ubiquitous) 0.47 1 Regulation of transcription from Pol II
promoter
AA053815 Hypothetical protein FLJ11767 0.47 1 Biological process unknown
R02716 Hypothetical protein FLJ14639 0.47 1 Biological process unknown
AA701545 Ribonuclease, RNase A family, k6 0.47 1 RNA catabolism
R93069 ESTs 0.47 1 Biological process unknown
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T54121 Cyclin E1 0.48 2 Regulation of cell cycle
H57309 Snail homolog 2 (Drosophila) 0.48 1 Development
T56948 Pumilio homolog 1 (Drosophila) 0.48 1 Biological process unknown
N93191 Voltage-dependent calcium channel gamma subunit-like protein 0.48 1 Biological process unknown
W33154 Formin binding protein 1 0.49 1 Biological process unknown
T95113 Viperin 0.49 1 Biological process unknown
AA679177 Butyrate-induced transcript 1 0.49 2 Activation of JUNK
W89074 ESTs 0.49 1 Biological process unknown
R97540 Down syndrome critical region gene 3 0.49 2 Intracellular protein transport
W60581 Brain expressed, X-linked 1 0.49 2 Biological process unknown
AA037352 Paired box gene 1 0.50 2 Biological process unknown
T53389 Fc fragment of IgG binding protein 0.50 1 Biological process unknown
N53480 Clone IMAGE:4794941, mRNA 0.50 3 Biological process unknown
AA410604 CDC16 cell division cycle 16 homolog (S. cerevisiae) 0.50 1 Cell cycle
N22827 Ferredoxin 1 0.50 1 Steroid metabolism
R95893 EST 0.50 1 Biological process unknown
AA872397 Lectin, galactoside-binding, soluble, 2 (galectin 2) 0.50 2 Heterophilic cell adhesion
H72588 ESTs 0.51 2 Biological process unknown
N92048 ESTs 0.51 1 Biological process unknown
N54793 ESTs 0.51 3 Biological process unknown
AA136699 ESTs 0.51 1 Biological process unknown
AA131466 Leukemia inhibitory factor receptor 0.51 4 Cell surface receptor linked signal
transduction
N33331 Peroxisome proliferative activated receptor, delta 0.52 3 Lipid metabolism
AA668527 Mucosal vascular addressin cell adhesion molecule 1 0.52 5 Cell adhesion
AA677706 Lactotransferrin 0.52 3 Iron ion transport
AA459390 Hypothetical protein FLJ22169 0.53 6 Biological process unknown
W02624 Kelch repeat and BTB (POZ) domain containing 2 0.53 6 Biological process unknown
AA984940 Ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) 0.53 11 RNA catabolism
AA464180 X-linked protein 0.53 9 Biological process unknown
R89765 Full-length insert cDNA clone YP91F02 0.54 11 Biological process unknown
AA102068 F-box and leucine-rich repeat protein 8 0.54 13 Biological process unknown
AA431429 ESTs, Weakly similar to A-kinase anchor protein DAKAP550 [D.
melanogaster]
0.54 20 Biological process unknown
AA009671 ESTs 0.54 21 Biological process unknown
AA458965 Natural killer cell transcript 4 0.55 19 Cell adhesion
H51438 ESTs 0.55 24 Biological process unknown
AA447593 Dynein, axonemal, light intermediate polypeptide 1 0.55 26 Cell motility
T98717 ESTs 0.56 26 Biological process unknown
AA485358 Seven transmembrane domain protein 0.56 25 Biological process unknown
AA022935 Formin-like 2 0.56 27 Regulation of transcription, DNA-dependent
H87770 Full-length insert cDNA YI27F12 0.56 25 Biological process unknown
AA024866 Hypothetical protein FLJ32731 0.56 28 Biological process unknown
AA055992 Hypothetical protein MGC17791 0.57 28 Biological process unknown
R92446 Cytokine receptor-like molecule 9 0.57 28 Biological process unknown
AA443971 ESTs 0.57 29 Biological process unknown
N79813 CDNA FLJ45930 fis, clone PLACE7000707 0.59 28 Biological process unknown
W80688 Zinc finger, CW-type with coiled-coil domain 1 0.59 29 Biological process unknown
N72185 ESTs 0.60 30 Biological process unknown
AA136666 CDNA: FLJ22750 fis, clone KAIA0478 0.60 30 Biological process unknown
AA133167 KIAA1644 protein 0.60 30 Biological process unknown
T84703 ESTs 0.61 30 Biological process unknown
AA029997 Collagen, type IV, alpha 5 (Alport syndrome) 0.62 30 Biological process unknown
AA953975 Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, epsilon
0.62 30 I-kappaB kinase/NF-kappaB cascade
W88801 Trans-prenyltransferase 0.63 30 Isoprenoid biosynthesis
N70632 Alcohol dehydrogenase, iron containing, 1 0.65 30 Metabolism
AA701081 Leucine-rich repeat transmembrane neuronal 2 protein 0.65 30 Biological process unknown
W93482 LOC374841 (LOC374841), mRNA 0.67 30 Biological process unknown
R20886 Stanniocalcin 2 0.68 30 Cell–cell signaling
aCorrelation coefficient between expression levels in 30 colorectal cancer cell lines (Ln) and the corresponding proportion of apoptotic cells after 72h exposure to 10mM
oxaliplatin (Ln). The correlation of all 9216 genes can be found in our website: www.augenlichtlab.com.
bNumber of times used in the leave-one-out cross-validation process.
cBiological process from Gene Ontology.
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cytotoxic effects of oxaliplatin (Rakitina et al, 2003). In addition,
the recently identified apoptosis inhibitor AVEN (Chau et al, 2000)
was found to be expressed at higher levels in cell lines that showed
reduced apoptosis in response to oxaliplatin.
The cytotoxic activities of oxaliplatin are believed to be linked to
DNA damage, and the levels of expression of the DNA repair
endonuclease ERCC1 (excision repair cross-complementing 1)
have been shown to be inversely correlated with response to
oxaliplatin (Shirota et al, 2001; Arnould et al, 2003). Although
ERCC1 was not represented in the 9K chips used in this study, our
microarray analyses identified at least four genes involved in DNA
repair mechanisms that were significantly correlated with the
ability of oxaliplatin to induce apoptosis in colorectal cancer cells
(see Table 1). The histone acetyltransferase HTATIP (HIV-1 Tat
interactive protein, 60kDa), postmeiotic segregation increased 2-
like 6 (PMS2L6), general transcription factor IIH, polypeptide 1
(GTF2H1), and the DNA ligase LIG4, showed higher levels of
expression in cell lines that are more resistant to oxaliplatin
treatment. In fact, at least LIG4 has been shown previously to
confer resistance to the related platinum compound cisplatin
(Chipitsyna et al, 2004).
In summary, this study investigates the molecular mechanisms
underlying the cytotoxic effects of oxaliplatin in colorectal cancer
cells in an attempt to identify different means of predicting
response to this chemotherapeutic agent. We demonstrate that
exposure of proliferating colorectal cancer cells to oxaliplatin
induces a G2/M arrest and a molecular cascade of events consistent
with an intrinsic mechanism of apoptosis. Moreover, the cytotoxic
effects of oxaliplatin were shown to be Bax and p53 depen-
dent using and isogenic in vitro system. Importantly, we
demonstrate that the expression profile of untreated tumour cells
can be used to predict response to oxaliplatin, and that this
approach outperforms the accuracy of p53 mutational status
as a predictive marker. The efficacy of this microarray-based
approach to predict response to oxaliplatin remains to be
confirmed in vivo. Collection of tumour samples from suitable
patient populations is currently ongoing at our institution to
test the value of these approaches, although completion of the
study is dependent upon prolonged follow-up periods to assess
response to therapy.
ACKNOWLEDGEMENTS
p53 and Bax null HCT116 cells were kindly provided by Dr Bert
Vogelstein (Johns Hopkins University School of Medicine). We
also thank Aldo Massimi and Dr Geoff Childs of the Albert Einstein
Microarray Facility for their assistance. Oxaliplatin was kindly
provided by Sanofi-Synthelabo (New York, NY).
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc).
REFERENCES
Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F,
Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-
Andre G, de Gramont A (1999) Multicenter phase II study of bimonthly
high-dose leucovorin, fluorouracil infusion, and oxaliplatin for meta-
static colorectal cancer resistant to the same leucovorin and fluorouracil
regimen. J Clin Oncol 17: 3560–3568
Arango D, Augenlicht LH (2001) New approaches to colorectal cancer
treatment. In Recent Research Developments in Cancer Pandalal SG (ed).
Vol 3, pp 385–395. Trivandrum: Transworld Research Network
Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH (2001) c-myc/
p53 interaction determines sensitivity of human colon carcinoma cells to
5-fluorouracil in vitro and in vivo. Cancer Res 61: 4910–4915
Arango D, Mariadason JM, Willson AJ, Yang W, Corner GA, Aran ˜es MJ,
Nicholas C, Augenlicht LH (2003) c-Myc overexpression sensitizes colon
cancer cells to camptothecin-induced apoptosis. Br J Cancer 89: 1757–1765
Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S (2003) Cellular
determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J
Cancer 39: 112–119
Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation.
Science 281: 1305–1308
Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS,
Pathak S, Benson A, Haller D, Heerdt BG (1997) Low-level c-myc
amplification in human colonic carcinoma cell lines and tumors: a
frequent, p53-independent mutation associated with improved outcome
in a randomized multi-institutional trial. Cancer Res 57: 1769–1775
Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK,
Hamilton S, Vogelstein B (1990) p53 gene mutations occur in
combination with 17p allelic deletions as late events in colorectal
tumorigenesis. Cancer Res 50: 7717–7722
Bertheault-Cvitkovic F, Jami A, Ithzaki M, Brummer PD, Brienza S, Adam
R, Kunstlinger F, Bismuth H, Misset JL, Levi F (1996) Biweekly
intensified ambulatory chronomodulated chemotherapy with oxaliplatin,
fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
J Clin Oncol 14: 2950–2958
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM,
Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain
G2 arrest after DNA damage. Science 282: 1497–1501
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams
J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in
human cancer cells alters the responses to therapeutic agents. J Clin
Invest 104: 263–269
Chau BN, Cheng EH, Kerr DA, Hardwick JM (2000) Aven, a novel inhibitor
of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 6: 31–40
Chipitsyna G, Slonina D, Siddiqui K, Peruzzi F, Skorski T, Reiss K,
Sawaya BE, Khalili K, Amini S (2004) HIV-1 Tat increases cell survival
in response to cisplatin by stimulating Rad51 gene expression. Oncogene
23: 2664
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J,
Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail
N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A
(2000) Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol 18:
2938–2947
de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C,
Raymond E, Moreau S, Le Bail N, Krulik M (1997) Oxaliplatin with high-
dose leucovorin and 5-fluorouracil 48-h continuous infusion in
pretreated metastatic colorectal cancer. Eur J Cancer 33: 214–219
Deacon E, Pongracz J, Griffiths G, Lord J (1997) Isoenzymes of protein
kinase C: differential involvement in apoptosis and pathogenesis. Mol
Pathol 50: 124–131
Desagher S, Martinou J-C (2000) Mitochondria as the central control point
of apoptosis. Trends Cell Biol 10: 369–377
Efron B, Tibshirani RJ (1993) An Introduction to the Bootstrap. New York:
Chapman & Hall
Ehrsson H, Wallin I, Yachnin J (2002) Pharmacokinetics of oxaliplatin in
humans. Med Oncol 19: 261–265
Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen
RD, Haas M, MacLeod CL, Howell SB (1997) In vitro and in vivo
resistance to cisplatin in cells that have lost DNA mismatch repair.
Cancer Res 57: 1841–1845
Garg A, Aggarwal BB (2002) Nuclear transcription factor-kappaB as a target
for cancer drug development. Leukemia 16: 1053–1068
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet
P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-
Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase
III multicenter randomized trial of oxaliplatin added to chronomodu-
lated fluorouracil–leucovorin as first-line treatment of metastatic
colorectal cancer. J Clin Oncol 18: 136–147
Sensitivity of colorectal cancer cells to oxaliplatin
D Arango et al
1945
British Journal of Cancer (2004) 91(11), 1931–1946 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yGourdier I, Del Rio M, Crabbe L, Candeil L, Copois V, Ychou M, Auffray C,
Martineau P, Mechti N, Pommier Y, Pau B (2002) Drug specific
resistance to oxaliplatin is associated with apoptosis defect in a cellular
model of colon carcinoma. FEBS Lett 529: 232–236
Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and
the mitochondria in apoptosis. Genes Dev 13: 1899–1911
Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI
(2004) Enhanced oxaliplatin-induced apoptosis following antisense Bcl-
xl down-regulation is p53 and Bax dependent: genetic evidence for
specificity of the antisense effect. Mol Cancer Ther 3: 169–178
Johnson CL, Lu D, Huang J, Basu A (2002) Regulation of p53 stabilization
by DNA damage and protein kinase C. Mol Cancer Ther 1: 861–867
Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between
cancer genetics and chemotherapy. Cell 108: 153–164
Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara
O, Zembutsu H, Yanagawa R, Hirata K, Takagi T, Nakamura Y (2001)
Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy
by cDNA microarray analysis of gene-expression profiles. Cancer Res 61:
6474–6479
Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani
R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger F, Gastiaburu J, Misset JL
(1993) Oxaliplatin activity against metastatic colorectal cancer. A phase
II study of 5-day continuous venous infusion at circadian rhythm
modulated rate. Eur J Cancer 29A: 1280–1284
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang
X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-
9 complex initiates an apoptotic protease cascade. Cell 91: 479–489
Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Induction of
apoptotic program in cell-free extracts: requirement for dATP and
cytochrome c. Cell 86: 147–157
Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21: 485–495
Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza
S, Itzhaki M, Metzger G, N’Daw D, Vignoud J, Abad A, Francois E,
Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M (1996) Two consecutive
phase II studies of oxaliplatin (L-OHP) for treatment of patients with
advanced colorectal carcinoma who were resistant to previous treatment
with fluoropyrimidines. Ann Oncol 7: 95–98
Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, Boland CR,
Zeitz M, Hanski C (2002) Cellular effects of CPT-11 on colon carcinoma
cells: dependence on p53 and hMLH1 status. Int J Cancer 101: 23–31
Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL,
Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A (1999)
Oxaliplatin added to the simplified bimonthly leucovorin and 5-
fluorouracil regimen as second-line therapy for metastatic colorectal
cancer (FOLFOX6). GERCOR. Eur J Cancer 35: 1338–1342
Marchetti P, Galla DA, Russo FP, Ricevuto E, Flati V, Porzio G, Ficorella C,
Cifone MG (2004) Apoptosis induced by oxaliplatin in human colon
cancer HCT15 cell line. Anticancer Res 24: 219–226
Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C,
Aranes MJ, Lesser M, Schwartz EL, Augenlicht LH (2003) Gene
expression profiling-based prediction of response of colon carcinoma
cells to 5-fluorouracil and camptothecin. Cancer Res 63: 8791–8812
Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct
transcriptional activator of the human bax gene. Cell 80: 293–299
Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y
(1998) Bax interacts with the permeability transition pore to induce
permeability transition and cytochrome c release in isolated mitochon-
dria. Proc Natl Acad Sci USA 95: 14681–14686
Orlandi L, Binda M, Folini M, Bearzatto A, Villa R, Daidone MG, Zaffaroni
N (2003) Ribozyme-mediated inhibition of PKCalpha sensitizes andro-
gen-independent human prostate cancer cells to cisplatin-induced
apoptosis. Prostate 54: 133–143
Orlowski RZ, Baldwin Jr AS (2002) NF-kappaB as a therapeutic target in
cancer. Trends Mol Med 8: 385–389
Petit T, Bearss DJ, Troyer DA, Munoz RM, Windle JJ (2003) p53-
independent response to cisplatin and oxaliplatin in MMTV-ras mouse
salivary tumors. Mol Cancer Ther 2: 165–171
Rakitina TV, Vasilevskaya IA, O’Dwyer PJ (2003) Additive interaction of
oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon
cancer cell lines results from inhibition of nuclear factor kappaB
signaling. Cancer Res 63: 8600–8605
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei
DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV
(2000) Colorectal tumors responding to 5-fluorouracil have low
gene expression levels of dihydropyrimidine dehydrogenase, thymi-
dylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:
1322–1327
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW,
Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville
EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene
expression database for the molecular pharmacology of cancer. Nat
Genet 24: 236–244
Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JF (1975) An electron-
microscope study of the mode of cell death induced by cancer-
chemotherapeutic agents in populations of proliferating normal and
neoplastic cells. J Pathol 116: 129–138
Seo YR, Chen EI, Smith ML (2002) Sensitivity of p53-deficient cells to
oxaliplatin and thio-TEPA (N,N0,N00 triethylenethiophosphoramide).
Breast Cancer Res Treat 72: 255–263
Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg
KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ (2001) ERCC1
and thymidylate synthase mRNA levels predict survival for colorectal
cancer patients receiving combination oxaliplatin and fluorouracil
chemotherapy. J Clin Oncol 19: 4298–4304
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D,
Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric
cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:
1107–1112
Tassone P, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML,
Tuccillo F, Turco MC, Venuta S (2002) Oxaliplatin (L-OHP) treatment of
human myeloma cells induces in vitro growth inhibition and apoptotic
cell death. Eur J Cancer 38: 1141–1147
Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte
JM, Staedel C, Lesuffleur T (2002) Resistance of colon cancer cells to
long-term 5-fluorouracil exposure is correlated to the relative level of
Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98:
498–504
Yang B, Eshleman JR, Berger NA, Markowitz SD (1996) Wild-type p53
protein potentiates cytotoxicity of therapeutic agents in human colon
cancer cells. Clin Cancer Res 2: 1649–1657
Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y,
Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y
(2002) Genome-wide cDNA microarray screening to correlate gene
expression profiles with sensitivity of 85 human cancer xenografts to
anticancer drugs. Cancer Res 62: 518–527
Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B (2000) Role of BAX in
the apoptotic response to anticancer agents. Science 290: 989–992
Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Apaf-1, a human
protein homologous to C. elegans CED-4, participates in cytochrome c-
dependent activation of caspase-3. Cell 90: 405–413
Sensitivity of colorectal cancer cells to oxaliplatin
D Arango et al
1946
British Journal of Cancer (2004) 91(11), 1931–1946 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y